Fexuprazan
- Generic Name
- Fexuprazan
- Indication
用于胃食管反流病（GERD）的治疗。
Sun Pharma Launches Fexuclue in India: A Novel Treatment for Erosive Esophagitis
• Sun Pharmaceutical has introduced Fexuclue (fexuprazan 40 mg), a novel potassium-competitive acid blocker, as a new treatment option for adults with all grades of erosive esophagitis in India.
• In a Phase 3 clinical trial involving Indian patients, Fexuclue demonstrated remarkable efficacy with over 95% of patients achieving erosive esophagitis healing within 8 weeks, while maintaining a favorable safety profile.
• The medication, licensed from South Korea's Daewoong Pharmaceutical, addresses significant unmet needs in erosive esophagitis management, a condition affecting approximately 9% of GERD patients in India.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath